{
  "id": "64041e97201352f04a00001e",
  "type": "yesno",
  "question": "Is daridorexant effective for insomnia?",
  "ideal_answer": "Yes. Daridorexant an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
    "http://www.ncbi.nlm.nih.gov/pubmed/35298826"
  ],
  "snippets": [
    {
      "text": "Daridorexant (Quviviq\u2122; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35298826",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daridorexant was superior to placebo in reducing wake time after sleep onset (MD\u2009=\u2009-13.26; 95% CI, -15.48 to -11.03; P\u2009<\u20090.00001), latency to persistent sleep (MD\u2009=\u2009-7.23; 95% CI, -9.60 to -4.85; P\u2009<\u20090.00001), with increasing the total sleep time (MD\u2009=\u200914.80; 95% CI, 11.18-18.42; P\u2009<\u20090.00001) and subjective total sleep time (MD\u2009=\u200914.80; 95% CI, 11.18-18.42], P\u2009<\u20090.00001). The 25 mg and 50 mg were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR)\u2009=\u20091.19; 95% CI, 1.05-1.35;, P\u2009=\u20090.005], specifically somnolence (RR\u2009=\u20091.19; 95% CI, 1.13-3.23; P\u2009=\u20090.005) and fatigue (RR\u2009=\u20092.01; 95% CI, 1.21-3.36; P\u2009=\u20090.007). Daridorexant is superior to placebo in improving sleep quality. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}